In addition, the immunoreactivity scores for GATA2-RCC and MDS-EB patients were predominantly negative to weakly positive (50% of GATA2-RCC and 44.45% of MDS-EB), with RCC patients showing moderately positive scores (43.75% of RCC, Figure 3D). This evidence concerns the gene GATA2 and myelodysplastic syndrome.